BLLNBillionToOne, Inc.
Price
End-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, nothing alarming, demanding price, the market undecided.
Founded with the mission to remove the fear of the unknown through powerful and accessible smNGS-based diagnostics, we have swiftly transitioned from an R&D-focused company to a proven commercial organization. In 2019, we launched our first prenatal product, UNITY. UNITY is the first NIPT that uses cfDNA to provide fetal risk assessment for recessive conditions such as sickle cell disease and cystic fibrosis without requiring a paternal sample or invasive procedures such as amniocentesis.
In the company’s own words · 10-K filed Mar 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
BillionToOne, Inc. (BLLN) reported revenue of $109M in Q2 2026 (quarter ended Jun 30, 2026), up 64% from the same quarter a year earlier. That came with a gross margin of 70% and net income of $8.1M (7.4% of revenue). For the full year FY2025, revenue was $305M (+100% year on year) and net income $7.5M. Its largest product in Q2 2026 was Prenatal at $94M, 86% of the disclosed total, well ahead of Oncology at 12%. The next results filing is expected around Nov 4, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance.Earnings release · press release
- Jun 29, 2026On June 23, 2026, BillionToOne, Inc. (the “Company”) entered into a lease (the “Lease”) with Whipple Road Portfolio, LLC (the “Landlord”), pursuant to which the Company will lease approximately 62,659 square feet of office and laboratory space at 3260 Whipple Road, Union City, CA 94587.Material agreement entered · Form 8-K
- May 6, 2026BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $109.4MThe company’s own SEC segment disclosure.
- Prenatal$94.2M86%
- Oncology$13.7M12%
- Clinical Trial Support And Other Services$1.5M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
The closest names by size in the same industry